Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Araxes Pharma Enters into Agreement with Janssen Biotech

Published: Friday, March 01, 2013
Last Updated: Friday, March 01, 2013
Bookmark and Share
Cancer drug discovery and development agreement to develop first-in-class therapeutics for the treatment of cancer.

Araxes Pharma LLC has announced that it has entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against a certain target for the treatment of cancer.

Araxes Pharma brings together a proven team of early drug developers. The scientific founders are Kevan Shokat, Ph.D., HHMI Investigator and Professor of Molecular and Cellular Pharmacology at UCSF, and Frank McCormick, Ph.D., FRS, Professor and Director of the Helen Diller Family Comprehensive Cancer Center at UCSF.

Joining them in the new venture are Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, Yi Liu, Ph.D., Chief Scientific Officer, and Pingda Ren, Ph.D., Senior Vice President of Chemistry.

Drs. Wilson, Liu, Ren and Shokat previously co-founded Intellikine, which discovered three drug candidates against the PI3K/mTOR pathway. The first drug candidate, a PI3Kdelta/gamma inhibitor, was licensed to Infinity Pharmaceuticals in July 2010 in a deal valued up to $489 million.

Separately, Intellikine advanced two more drug candidates-a TORC1/2 inhibitor and a PI3Kalpha inhibitor-into human clinical trials.

In January 2012, Millennium Pharmaceuticals, the Takeda Oncology Company, acquired Intellikine in a deal valued up to $310 million.

The Intellikine co-founders recently reunited to form Wellspring Biosciences, a pharmaceutical incubator focused on the discovery and development of drugs targeting signal transduction networks for the treatment of cancer and other serious diseases.

Wellspring is organized as a drug discovery incubator, with its scientific programs organized in separate, asset-centered affiliates. Araxes Pharma LLC represents the first publicly announced affiliate.

Under the agreement with Janssen Biotech, Araxes Pharma will advance its program through Phase I to clinical proof-of-concept. Thereafter, Janssen Biotech will have sole responsibility for the continued development and worldwide commercialization of products arising under the agreement.

Araxes Pharma will receive an upfront payment and research and development funding and is eligible to receive milestone payments in addition to tiered royalties on the worldwide sales of products under the agreement.

"We are delighted to work with Janssen on a very exciting approach for the treatment of patients with cancer," said Troy Wilson, President and CEO of Araxes Pharma.

Wilson continued, "Their sophisticated outlook and capabilities for development of molecularly-targeted therapeutics will enable us to accelerate development of our novel, high-quality small molecules."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
How Small RNA Helps Form Memories
In a new study, a team of scientists at Scripps Florida has found that a type of genetic material called "microRNA" (miRNA) plays surprisingly different roles in the formation of memory in animal models.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!